Pfizer EBITDA 2010-2023 | PFE
Pfizer annual and quarterly EBITDA history from 2010 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Pfizer EBITDA for the quarter ending December 31, 2023 was $-2.939B, a 149.81% decline year-over-year.
- Pfizer EBITDA for the twelve months ending December 31, 2023 was $6.512B, a 83.72% decline year-over-year.
- Pfizer 2023 annual EBITDA was $6.512B, a 83.72% decline from 2022.
- Pfizer 2022 annual EBITDA was $40.008B, a 62.48% increase from 2021.
- Pfizer 2021 annual EBITDA was $24.624B, a 90.43% increase from 2020.
Pfizer Annual EBITDA
(Millions of US $) |
| 2023 |
$6,512 |
| 2022 |
$40,008 |
| 2021 |
$24,624 |
| 2020 |
$12,931 |
| 2019 |
$12,465 |
| 2018 |
$11,822 |
| 2017 |
$19,991 |
| 2016 |
$17,902 |
| 2015 |
$16,981 |
| 2014 |
$18,786 |
| 2013 |
$21,594 |
| 2012 |
$22,919 |
| 2011 |
$22,993 |
| 2010 |
$21,811 |
| 2009 |
$15,716 |
Pfizer Quarterly EBITDA
(Millions of US $) |
| 2023-12-31 |
$-2,939 |
| 2023-09-30 |
$-1,870 |
| 2023-06-30 |
$3,494 |
| 2023-03-31 |
$7,827 |
| 2022-12-31 |
$5,900 |
| 2022-09-30 |
$10,126 |
| 2022-06-30 |
$13,394 |
| 2022-03-31 |
$10,588 |
| 2021-12-31 |
$4,326 |
| 2021-09-30 |
$7,488 |
| 2021-06-30 |
$6,914 |
| 2021-03-31 |
$5,896 |
| 2020-12-31 |
$1,811 |
| 2020-09-30 |
$3,656 |
| 2020-06-30 |
$3,271 |
| 2020-03-31 |
$4,193 |
| 2019-12-31 |
$-3,799 |
| 2019-09-30 |
$4,511 |
| 2019-06-30 |
$5,794 |
| 2019-03-31 |
$5,959 |
| 2018-12-31 |
$-4,610 |
| 2018-09-30 |
$5,378 |
| 2018-06-30 |
$5,538 |
| 2018-03-31 |
$5,516 |
| 2017-12-31 |
$3,881 |
| 2017-09-30 |
$5,230 |
| 2017-06-30 |
$5,315 |
| 2017-03-31 |
$5,565 |
| 2016-12-31 |
$3,305 |
| 2016-09-30 |
$4,417 |
| 2016-06-30 |
$4,864 |
| 2016-03-31 |
$5,316 |
| 2015-12-31 |
$3,258 |
| 2015-09-30 |
$4,630 |
| 2015-06-30 |
$4,796 |
| 2015-03-31 |
$4,297 |
| 2014-12-31 |
$3,478 |
| 2014-09-30 |
$5,008 |
| 2014-06-30 |
$5,374 |
| 2014-03-31 |
$4,926 |
| 2013-12-31 |
$4,532 |
| 2013-09-30 |
$5,505 |
| 2013-06-30 |
$5,913 |
| 2013-03-31 |
$5,644 |
| 2012-12-31 |
$4,667 |
| 2012-09-30 |
$5,399 |
| 2012-06-30 |
$6,539 |
| 2012-03-31 |
$6,314 |
| 2011-12-31 |
$4,371 |
| 2011-09-30 |
$6,303 |
| 2011-06-30 |
$6,270 |
| 2011-03-31 |
$6,049 |
| 2010-12-31 |
$3,793 |
| 2010-09-30 |
$5,992 |
| 2010-06-30 |
$6,414 |
| 2010-03-31 |
$5,612 |
| 2009-12-31 |
$1,735 |
| 2009-09-30 |
$5,100 |
| 2009-06-30 |
$4,127 |
| 2009-03-31 |
$4,754 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$143.829B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
